a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 12,

A. Federal Reserve Bank of Richmond (A. Linwood Gill III, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. Shore Financial Čorporation, Onley, Virginia; to become a bank holding company by acquiring 100 percent of the voting shares of Shore Bank, Onley, Virginia.

**B. Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

1. First United Bancshares, Inc., El Dorado, Arkansas; to merge with Citizens National Bancshares of Hope, Inc., Hope, Arkansas, and thereby indirectly acquire Citizens National Bank of Hope, Hope, Arkansas, and Peoples Bank and Loan Company, Lewisville, Arkansas.

C. Federal Reserve Bank of Kansas City (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

*I. FNB Financial Services, Inc. ESOP*, Durant, Oklahoma; to acquire .3 percent of the voting shares of FNB Financial Services, Inc., Durant, Oklahoma, and thereby indirectly acquire The First National Bank in Durant, Durant, Oklahoma.

Board of Governors of the Federal Reserve System, December 15, 1997.

#### Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 97–33087 Filed 12–17–97; 8:45 am] BILLING CODE 6210–01–F

### FEDERAL RESERVE SYSTEM

#### Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other

company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 2, 1998.

A. Federal Reserve Bank of Kansas City (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

 Gold Banc Corporation, Inc., Leawood, Kansas; to acquire Midwest Capital Management, Inc., Kansas City, Missouri, and thereby indirectly engage in financial and investment advisory activities, pursuant to § 225.28(b)(6) of the Board's Regulation Y; agency transactional services for customer investments including securities brokerage, riskless principal transactions and private placement services, pursuant to §§ 225.28(b)(7)(i), (ii), and (iii) of the Board's Regulation Y; investment transactions as principal, including underwriting and dealing in government obligations and money market instruments, pursuant to § 225.28(b)(8)(i) of the Board's Regulation Y; investing and trading activities, i.e. engaging as principal in financial futures, pursuant to § 225.28(b)(8)(ii)(B) of the Board's Regulation Y; providing management consulting advice, pursuant to § 225.28(b)(9)(A) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, December 15, 1997.

#### Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 97–33086 Filed 12–17–97; 8:45 am] BILLING CODE 6210–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Office of the Secretary

### **Findings of Scientific Misconduct**

**AGENCY:** Office of the Secretary, HHS. **ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

S. Ashraf Imam, Ph.D., University of Southern California: Based on an investigation report forwarded to the Office of Research Integrity (ORI) by the University of Southern California (USC) as well as information obtained by ORI during its oversight review, ORI found that Dr. Imam, an Associate Professor in the Department of Pathology, USC, engaged in scientific misconduct by including plagiarized material in a grant application submitted to the National Cancer Institute (NCI), National Institutes of Health (NIH).

Specifically, Dr. Imam's NIH grant application contained extensive paraphrasing of the text of another researcher's independent grant application to a state agency. Dr. Imam had been given that application by a colleague in confidence. The colleague was a reviewer on the state grant application and requested that Dr. Imam evaluate it and return the application to him.

The other researcher's application was subsequently funded. Dr. Imam paraphrased or copied into his NIH application all of the other researcher's specific aims, the background on proposed methods, the experimental design and research plan, and most of the references; only the preliminary results sections of Dr. Imam's application were different.

Dr. Imam has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has agreed, for the three (3) year period beginning December 8, 1997, to exclude himself voluntarily from:

(1) any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations); and

(2) serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

No scientific publications were required to be corrected as part of this Agreement.

## FOR FURTHER INFORMATION CONTACT: Acting Director Division of Research

Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330. Chris B. Pascal, J.D.,

Acting Director, Office of Research Integrity. [FR Doc. 97–33035 Filed 12–17–97; 8:45 am] BILLING CODE 4160–17–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request, Proposed Projects

Title: IRS Project 1099.

OMB No.: New Collection.

Description: A voluntary program
which provides States' Child Support

Enforcement agencies upon there request access to all of the earned and unearned income information reported to IRS by employers and financial institutions. The IRS 1099 information is used to locate noncustodial parents and to verify income and employment, which has proven essential to accurately establishing and enforcing child support obligations.

*Respondents:* State, Local, or Tribal Govt.

### ANNUAL BURDEN ESTIMATES

Instrument	Number of re- spondents	Number of re- sponses per respondent	Average bur- den hours per response	Total burden hours
OCSE 1099 Request Records	43	12	1	1,032

Estimated Total Annual Burden Hours: 1,032.

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: December 15, 1997.

#### **Bob Sargis**,

Acting Reports Clearance Officer.
[FR Doc. 97–33083 Filed 12–17–97; 8:45 am]
BILLING CODE 4184–01–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N-0517]

Changes in Medical Device Tracking and Postmarket Surveillance Authority

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: Changes in medical device tracking and postmarket surveillance authority under the Food and Drug Administration Modernization Act of 1997. The topic to be discussed is postmarket controls, including tracking and/or surveillance of devices.

Date and Time: The meeting will be held on January 15, 1998, 9 a.m. to 3 p.m.

Location: The meeting will be held at the University of Maryland Auditorium, 9640 Gudelsky Dr., Rockville, MD.

Contact: Casper E. Uldriks, Center for Devices and Radiological Health (HFZ–300), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–4692, FAX 301–594–4610.

Registration and Requests for Oral Presentations: Send registration information (including name, title, firm name, address, telephone, and fax number) and written material and requests to make oral presentations to the contact person by January 5, 1998. Written comments may be submitted to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, by January 5, 1998.

If you need special accommodations due to a disability, please contact Casper E. Uldriks at least 7 days in advance of the meeting.

Transcripts: Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page.

The agency is interested in discussing the statutory changes concerning tracking and postmarket surveillance under the Food and Drug Administration Modernization Act of 1997 and whether the agency should develop additional criteria to use to determine whether tracking or postmarket surveillance requirements should be ordered by FDA. The agency would like to supplement the statutory criteria with additional nonbinding criteria to help determine which devices may need to be added or removed from the list of devices subject to tracking and/or postmarket surveillance requirements. FDA intends to publish its revised lists by February 19, 1998, the effective date of the new law.

By way of example, additional criteria that would support a tracking order might include the likelihood of a recall, or the likelihood of irreversible clinical outcomes. Additional criteria that might not support a tracking order, for example, might include current, standard clinical practices that mitigate risk. Additional criteria that would support a postmarket surveillance order might include, for example, the use of a new technology or the need to assess a new public health issue based on measurable outcomes. Additional criteria that would not support a